Advertisement

Lasers in Medical Science

, Volume 11, Issue 1, pp 23–29 | Cite as

m-THPC photodynamic therapy for head and neck cancer

  • M. G. Dilkes
  • M. L. DeJode
  • A. Rowntree-Taylor
  • J. A. McGilligan
  • G. S. Kenyon
  • P. McKelvie
Original Articles

Abstract

Over the past 30 months, the authors have treated a wide variety of head and neck cancer patients with meta-tetrahydroxyphenylchlorin (mTHPC)-mediated photodynamic therapy (PDT). This drug is a powerful, second-generation photosensitizer with significant advantages over earlier drugs. Treatment ranged from palliation and adjunctive to curative procedures. Results to date are very encouraging, with marked advantages over standard methods of treatment with respect to morbidity, both functional and aesthetic. Potential cure rates remain essentially unchanged, very much dependent on the stage of the tumour. These promising early results justify a multicentre study for treatment of early head and neck cancer using this drug and light combination. This is now underway.

Key words

Photodynamic therapy Head and neck cancer Chlorin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Johansen LV, Overgaard J, Overgaard M, Birkler N, Fisker A. Squamous cell carcinoma of the oropharynx: An analysis of 213 consecutive patients scheduled for primary radiotherapy.Laryngoscope 1990,100:985–90PubMedGoogle Scholar
  2. 2.
    Pass HI. Photodynamic therapy in clinical oncology: mechanisms and clinical use.J Natl Cancer Inst 1993,85:443–56PubMedGoogle Scholar
  3. 3.
    Bonnet R, Berenbaum MC. Porphyrins as photosensitizers. In: Bock G, Harnett S. (eds)Photosensitizing Compounds: their Chemistry, Biology and Clinical Use. Chichester, Wiley, CIBA Foundation Symposium146:40–59, 1989Google Scholar
  4. 4.
    Gomer CJ, Rucker N, Murphree AL. Preferential cell photosensitivity following porphyrin photodynamic therapy.Canc Res 1988,40:4539–42Google Scholar
  5. 5.
    Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumour.Canc Res 1976,36:2326–9Google Scholar
  6. 6.
    Henderson BW, Wadlow SM, Mang TS, Potter WR et al. Tumour destruction and kinetics of tumour cell death in two experimental mouse tumours following photodynamic therapy.Canc Res 1985,45:572–6Google Scholar
  7. 7.
    Berenbaum MC, Akande SL, Bonnet R et al. meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitizers with favourable selectivity.Br J Cancer 1986,54:717–25PubMedGoogle Scholar
  8. 8.
    Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder.J Urol 1976,115:150–1PubMedGoogle Scholar
  9. 9.
    Dilkes MG, DeJode ML. Alternative light sources for PDT (Abstract).Lasers Med Sci 1996, in pressGoogle Scholar
  10. 10.
    Ris HB, Altermatt HJ, Stewart CM et al. Photodynamic therapy with m-Tetrahydroxyphenylchlorin in vivo: optimisation of the therapeutic index.Int J Cancer 1993,55:245–9PubMedGoogle Scholar
  11. 11.
    Dilkes MG. The Role of Adjunctive Intra-operative Photodynamic Therapy in Reducing Local Recurrence After Radical Neck Dissection—Safety and Efficacy Studies. MS Thesis, London University, UK, 1996.Google Scholar
  12. 12.
    Grant WE, Hopper C, MacRobert AJ et al. Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid.Lancet 1993,342:147–8PubMedGoogle Scholar
  13. 13.
    Buchanan RB, Carruth JAS, McKenzie AL, RhysWilliams S. Photodynamic therapy in the treatment of malignant tumours of the skin and head and neck.Eur J Surg Oncol 1989,15:400–6PubMedGoogle Scholar
  14. 14.
    Schweizer VG. Photodynamic therapy for related mucocutaneous Kaposi's sarcoma.Otolaryngol Head Neck Surg 1990,102:639–49PubMedGoogle Scholar
  15. 15.
    Feyh J, Goetz A, Muller W et al. Photodynamic therapy in head and neck cancer.J Photochem Photobiol 1990,7:353–8Google Scholar
  16. 16.
    Gluckman JL. Photodynamic therapy for head and neck neoplasms.Otolaryngol Clin N Am 1991,24:1559–67Google Scholar
  17. 17.
    Monnier Ph, Savary M, Fontolliet Ch et al. Photodetection and photodynamic therapy of early SCC of the pharynx, oesophagus and tracheobronchial tree.Lasers Med Sci 1990,5:149–69Google Scholar
  18. 18.
    Biel MA. Photodynamic therapy and the treatment of neoplastic disease of the larynx.Laryngoscope 1994,104:399–403PubMedGoogle Scholar
  19. 19.
    Schweizer VG, Bologna S, Batra SK. Photodynamic therapy for treatment of esophageal cancer: a preliminary report.Laryngoscope 1993,103:669–703Google Scholar
  20. 20.
    Grant WE, Hopper C, Speight PM et al. Photodynamic therapy of malignant and premalignant lesions in patients with ‘field cancerisation’ of the oral cavity.J Laryngol Otol 1993,107:1140–5PubMedGoogle Scholar
  21. 21.
    Gluckman JL. Hematoporphyrin photodynamic therapy: is there truly a future in head and neck oncology? Reflections on a 5 year experience.Laryngoscope 1991,101:36–41PubMedGoogle Scholar
  22. 22.
    Dilkes MG, DeJode ML. meta-Tetrahydroxyphenylchlorin mediated photodynamic therapy. Experience and thoughts after 17 treatments.Proc S.P.I.E. 1995,2371:256–61Google Scholar
  23. 23.
    Davis RK, Smith LF, Thurgood RF et al. Intraoperative phototherapy (PDT) and surgical resection in a mouse neuroblastoma model.Lasers Surg Med 1990,10:275–9PubMedGoogle Scholar

Copyright information

© W.B. Saunders Company Ltd. 1996

Authors and Affiliations

  • M. G. Dilkes
    • 1
  • M. L. DeJode
    • 2
  • A. Rowntree-Taylor
    • 3
  • J. A. McGilligan
    • 1
  • G. S. Kenyon
    • 1
  • P. McKelvie
    • 1
  1. 1.ENT DepartmentThe Royal London HospitalWhitechapel, LondonUK
  2. 2.Surgical UnitThe Royal London HospitalWhitechapel, LondonUK
  3. 3.Scotia PharmaceuticalGuildfordUK

Personalised recommendations